Bavarian Nordic jumps on positive COVID-19 vaccine trial results

ExpreS2ion Biotech Holding AB

09/08/2021 08:50

** Shares in Bavarian Nordic  BAVA.CO  rise more than 5.5%
after the Danish biotechnology company reported positive initial
results from first-in-human trial of its COVID-19 vaccine
 urn:newsml:reuters.com:*:nASN001J3P
    ** The company says that results demonstrate that vaccine
was well tolerated across all dose groups
    ** Final results are expected in the second half of 2021
    ** The stock is on track for its best day in 5 months,
having gained nearly 53 year-to-date
    ** Peer ExpreS2ion Biotech  EXPRS2.ST , which works on
manufacturing and scaling-up of the vaccine, rises 14%   

 (Reporting by Jagoda Darlak)
 ((jagoda.darlak@tr.com))